A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

a study on Colorectal Cancer Pancreatic Ductal Adenocarcinoma Biliary Tract Cancer Gastrointestinal Cancer

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
study ends around

Description

Summary

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn:

  • About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it
  • How many people have the cancer respond (get smaller or go away) to treatment

Official Title

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Keywords

Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer, Biliary Tract Neoplasms, Gastrointestinal Neoplasms, Leucovorin, Pembrolizumab, Fluorouracil, Levoleucovorin, Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures, Cisplatin, Sacituzumab tirumotecan + Chemotherapy, Sacituzumab tirumotecan + Cisplatin + Pembrolizumab

Eligibility

You can join if…

Open to people ages 18 years and up

The main inclusion criteria include but are not limited to the following:

  • Has one of the following cancers:
  • For participants who have received prior therapy for cancer: Has recovered from any side effects due to previous cancer treatment

You CAN'T join if...

The main exclusion criteria include but are not limited to the following:

  • History of severe eye disease
  • For participants who have received prior therapy for cancer: Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention
  • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

Locations

  • UCLA ( Site 0317) accepting new patients
    Los Angeles California 90095 United States
  • UCHealth Highlands Ranch Hospital ( Site 0325) accepting new patients
    Highlands Ranch Colorado 80129 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Merck Sharp & Dohme LLC
Links
Merck Clinical Trials Information Plain Language Summary
ID
NCT06428409
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 180 study participants
Last Updated